[Form 4] Annovis Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Michael B. Hoffman, a director of Annovis Bio, Inc. (ANVS), reported multiple open-market purchases of common stock on 08/19/2025. The Form 4 shows four acquisitions totaling 18,645 shares at prices ranging from $2.57 to $2.60, recorded as purchases (code A). After these transactions Mr. Hoffman directly beneficially owned 1,464,929 shares, and 223,357 shares were held indirectly in the 2018 Jane and Michael Hoffman Descendants Trust, over which he has voting and investment power.

The filing was signed by an attorney-in-fact on 08/20/2025. The form identifies Mr. Hoffman as a director and a single reporting person for this report.

Positive

• Insider purchases: Michael B. Hoffman acquired a total of 18,645 shares on 08/19/2025, disclosed on Form 4.
• Clear disclosure: The filing specifies transaction dates, per-share prices ($2.57–$2.60), and post-transaction beneficial ownership totals.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director purchased 18,645 ANVS shares across four trades at ~$2.57–$2.60, increasing direct holdings to 1.46M shares.

The filing documents aggregate acquisitions totaling 18,645 common shares on 08/19/2025 executed at per-share prices between $2.57 and $2.60. These are recorded as non-derivative purchases and raise the reporting person’s direct beneficial ownership to 1,464,929 shares. From a reporting standpoint, this is a standard Section 16 disclosure showing insider purchases; the data are precise and fully disclosed in the Form 4.

Corporate Governance Expert

TL;DR: Director-level insider bought shares and holds additional shares indirectly via a family trust; disclosure appears complete.

The report identifies Michael B. Hoffman as a director and notes indirect ownership via the 2018 Jane and Michael Hoffman Descendants Trust with 223,357 shares, where he retains voting and investment power. The Form 4 includes signature by an attorney-in-fact and lists transaction codes and prices, meeting standard disclosure requirements for changes in beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Michael B

(Last) (First) (Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		A		6,717	A	$2.6	1,453,001	D
Common Stock	08/19/2025		A		5,283	A	$2.59	1,458,284	D
Common Stock	08/19/2025		A		5,545	A	$2.58	1,463,829	D
Common Stock	08/19/2025		A		1,100	A	$2.57	1,464,929	D
Common Stock								223,357	I	The 2018 Jane and Michael Hoffman Descendants Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

	/s/ Maria Maccecchini Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Michael B. Hoffman report on Form 4 for ANVS?

He reported four non-derivative acquisitions totaling 18,645 common shares on 08/19/2025 at prices between $2.57 and $2.60.

How many ANVS shares does Michael B. Hoffman beneficially own after these trades?

Following the reported transactions he directly beneficially owned 1,464,929 shares and indirectly held 223,357 shares in a family trust.

What is the nature of the indirect ownership disclosed?

The indirect holdings are held in the 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.

When was the Form 4 signed and who signed it?

The Form 4 shows a signature by Maria Maccecchini, Attorney-in-Fact dated 08/20/2025.

What role does Michael B. Hoffman have at Annovis Bio, Inc.?

The form identifies him as a Director of Annovis Bio, Inc. (ANVS).